+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients

Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients

Fundamental and Clinical Pharmacology 9(6): 593-603

Administration of different doses of formoterol from a recently developed multiple dose dry powder device was tested in a placebo-controlled, single-centre, double-blind, within-patient trial. Eighteen patients of both sexes, aged 18-65 years, with a FEV1 of 50-80% and a reversibility of at least 15% were randomized. During four treatment periods of 8 days each, divided by approximately 6 days, patients received placebo or 6, 12 or 24 micrograms (PL, F6, F12 and F24, respectively) of formoterol from the powder device. Efficacy parameters (FEV1) and safety parameters (primarily pulse rate, electrocardiogram [ECG] and subjective experiences) were evaluated during 24 hours on the last day of each treatment period. Peak flow and the number of puffs of used rescue medication (100 micrograms of salbutamol) were registered during treatment periods. For efficacy analysis, 17 patients remained. For FEV1 0.5 hour before the last dose and 12 and 24 hours after the last dose all formoterol doses were statistically significant superior to placebo. Clinically relevant differences from placebo were found up to 8 hours (F6) and 12 hours (F12 and F24). The difference between doses was clinically relevant for the area under the FEV1 curve between F6 and F24. PEF on the treatment days corresponded to these findings. In three cases of 13 reported adverse effects, the relation to trial medication was probable (tremor) or possible (insomnia and hyperaesthesia). All other safety measurements showed no significant differences. We conclude that formoterol dry powder in the newly developed multiple dose inhalation device is an effective and safe beta 2-stimulant with a long duration of action in doses of 6, 12 and 24 micrograms. The 24 micrograms dose is superior to the 6 micrograms dose. Efficacy decreased considerably between the 12th and 24th hour after dosing.

(PDF emailed within 0-6 h: $19.90)

Accession: 046009194

Download citation: RISBibTeXText

PMID: 8808181

DOI: 10.1111/j.1472-8206.1995.tb00538.x

Related references

Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone. Ugeskrift for Laeger 158(49): 7092-7096, 1996

Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice daily formoterol 12 mug. European Respiratory Journal Supplement 10(25): 103S, Sept, 1997

Formoterol dry-powder inhalation--Novartis/SkyePharma: Foradil MDDPI, Foradil MDPI, Foradil SkyeHaler, formoterol fumarate dry-powder inhalation. Drugs in R&d 5(3): 162-163, 2004

A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration; International Review of Thoracic Diseases 72 Suppl 1: 28-34, 2005

Evaluation of a novel breath activated inhalation device in asthmatic patients. European Respiratory Journal 7(SUPPL 18): 52S, 1994

Bronchodilatation effects of dry powder formoterol fumarate in asthmatic patients. Journal of the Medical Association of Thailand 80(10): 658-661, 2000

Evaluation of inhalation device usage techniques in medical personnel and asthmatic patients. European Respiratory Journal 12(Supplement 29): 10s, December, 1998

Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients. Journal of Investigational Allergology and Clinical Immunology 8(5): 265-270, 1998

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. European Respiratory Journal 10(11): 2484-2489, 1998

Formoterol fumarate inhalation powder vs albuterol inhalation for treatment of asthma in the acute setting. Journal of Allergy & Clinical Immunology 113(2 Supplement): S34, February, 2004

Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 101(5): 1376-1381, 1992

Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. European Respiratory Journal 12(3): 573-579, 1998

Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. Pulmonary Pharmacology and Therapeutics 21(3): 551-557, 2008

Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Current Medical Research and Opinion 23(10): 2405-2413, 2010

Formoterol as Dry Powder Inhalation. Chest Journal 101(5): 1376-1381, 1992